Key statistics
Short selling activityProvided by S&P Global Market Intelligence
| Open | 16.71 |
|---|---|
| High | 16.71 |
| Low | 16.71 |
| Bid | 16.28 |
| Offer | 16.34 |
| Previous close | 16.71 |
| Average volume | -- |
|---|---|
| Shares outstanding | 169.18m |
| Free float | 168.26m |
| P/E (TTM) | 14.96 |
| Market cap | 3.93bn USD |
| EPS (TTM) | 1.55 USD |
Data delayed at least 15 minutes, as of Jul 30 2024.
More ▼
Press releases
- Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026
- Acadia Pharmaceuticals Provides Update on Regulatory Submission for Trofinetide for the Treatment of Rett Syndrome in the European Union
- Acadia Pharmaceuticals Provides Business and Pipeline Updates at 44th Annual J.P. Morgan Healthcare Conference
- Acadia Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026
- Acadia Pharmaceuticals Announces FDA Approval of DAYBUE® STIX (trofinetide) for Oral Solution, a New Powder Formulation of Trofinetide for the Treatment of Rett Syndrome
- Acadia Pharmaceuticals to Participate in Citi’s 2025 Global Healthcare Conference
More ▼
